CytoDyn Appoints Christopher Recknor, M.D., as Chief
Dr. Recknor will proceed to supervise the corporate's long-range COVID-19 and Part 2 NASH research VANCOUVER, Wash., March 16, 2021 (GLOBE NEWSWIRE) - CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Firm"), a late-stage biotechnology…